ClinicalTrials.gg
RecruitingNCT02936791EPOCUpdated Apr 27, 2026

Early PKD Observational Cohort Study

An observational study in Polycystic Kidney Disease, sponsored by University of Kansas Medical Center. Recruiting at 3 sites in United States. Open to participants aged 4 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by University of Kansas Medical Center · Observational

How we know

From the registry’s dates

  • Started Apr 2016; still recruiting 10 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
4 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Polycystic Kidney Diseases with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Polycystic Kidney Diseases · United States.

Planned enrollment
6th of 10
250 · median 300
Started
2016
with 3 others
Observational
10 of 32
5 open now
Registered
21st of 32
by date
Lead sponsor
3 of 32
University of Kansas Medical Center

Among the 32 studies in Polycystic Kidney Diseases with a site in United States, this one is the 6th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2016, is one of 10 observational ones, and was the 21st registered.

Polycystic Kidney Diseases

59 studies on the registry are indexed under Polycystic Kidney Diseases; 12 are open to participants now.

Browse Polycystic Kidney Diseases studies →

Open to participants now

9 of the 32 studies in Polycystic Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Polycystic Kidney Diseases studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Polycystic Kidney Diseases with a site in United States, or all of them as a file.
02

Study summary

This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.

Read the detailed description

In polycystic kidney disease (PKD), renal cysts form in utero and progressively enlarge due to aberrant proliferation of the cyst-lining cells and accumulation of fluid within the expanding cyst cavity. Over decades of unrelenting cyst growth, renal function declines due to the loss of functional tissue, eventually leading to kidney failure and the need for renal replacement therapy, such as dialysis or kidney transplantation.

Effective therapies for the treatment of PKD will need to be delivered as early as possible, before a measurable decline in kidney function, to preserve functional tissue. Currently, it is difficult to make an accurate prognosis of the progression of early-stage PKD since the growth of microscopic cysts is difficult to detect by standard imaging modalities and changes in total kidney volume measured within a reasonable time period are too small to be informative. Even though early cysts may not cause detectable changes in total kidney volume, their progressive enlargement damages the surrounding tissue and is a prelude to chronic kidney disease.

Current blood and urine tests provide important information on the decline of kidney function; however, these tests are not useful for monitoring early events of PKD such as initial cyst growth and damage to neighboring tissue. Clearly, novel biomarkers of early cystic disease need to be discovered to develop appropriate clinical tests to monitor the progression of early stage PKD. These tests will be important to identify patients at risk of rapid progression and of need of therapeutic intervention and to monitor the effectiveness of the therapeutic drug. The PKD Biomarkers Repository will allow approved researchers to obtain blood and urine samples for biomarker discovery and development of appropriate biomarker assays for prognosis of early PKD.

This observational study is currently recruiting for three groups: 1) individuals diagnosed with relatively early PKD as defined by total kidney volume and estimated GFR, 2) unaffected or undiagnosed family members, preferably siblings, 3) normal volunteers with no family history of renal disease.

03

Conditions studied

  • Polycystic Kidney Disease

Keywords

  • autosomal dominant polycystic kidney disease
  • ADPKD
  • PKD biomarkers
  • Kidney Institute
  • University of Kansas Medical Center
04

Who can participate

Ages eligible
4 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The Study Population will include individuals clinically diagnosed with PKD and meet the inclusion criteria, their family members with not been diagnosed or have been determined not to have cysts within their kidneys and normal volunteers that will serve as a control group for the study.

Eligibility criteria

Inclusion Criteria:

  • Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD):

    • Family history of PKD
    • All races and ethnic groups
    • (GFR) >80 ml/min per 1.73 m2
  • Inclusion for Healthy Volunteers:

    • Male or female with no family history of kidney disease
    • All races and ethnic groups
    • Normal GFR

Exclusion Criteria:

  • Non-insulin or insulin-dependent diabetes mellitus
  • Systemic illness (i.e.systemic lupus erythematosus, vasculitis)
  • Unable to provide written
  • Unavailable for magnetic resonance imaging (MRI) and blood/urine collection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Individuals diagnosed with PKD

    Individuals that have been diagnosed and meet the study's definition of early stage PKD.

  • Individuals with a family history of PKD

    Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD

  • Normal individuals for the comparison

    Normal volunteers with no family history of PKD or other kidney diseases.

06

What researchers measure

Primary outcomes

  1. Collect blood and urine samples from affected and unaffected cohorts for basic and translational research

    The study will establish a repository of blood and urine from individuals with early stage PKD, unaffected/undiagnosed family members and normal volunteers.

    Time frame: 10 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2016 (actual). Primary completion is estimated for Jun 2030, 170 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2016
First posted
Oct 18, 2016
StartActual
Apr 2016
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2031
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02936791
Responsible party
Sponsor
First posted
Oct 18, 2016
Start date
Apr 2016
Primary completion
Jun 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Apr 27, 2026

Study contacts

Cathy Creed, RN
Contact
ccreed@kumc.edu
913-588-0053
Alan SL Yu, MD
principal investigator · University of Kansas Medical Center
Darren P Wallace, PhD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion